Assessing Patient Safety and Mortality Risk Associated with Atypical Antipsychotic Use versus Pimavanserin in Management of Parkinson’s disease Psychosis (PDP)

This course will examine medication management for Parkinson’s disease psychosis and best practices for patient safety and efficacy to ensure improved patient outcomes.

Provider:Postgraduate Institute for Medicine
Activity Link: https://education.pmdalliance.org/courses/no-algorithm
Start Date: 2023-01-31 06:00:00
End Date: 2023-01-31 06:00:00
Credit Details: AMA PRA Category 1 Credit™️: 1.75 hours
Commercial Support: Source: Acadia - Amount: 99719.0 - Is Kind Support: False
Activity Type: Enduring Material
CME Finder Type: Online Learning
Fee to Participate: No, it's free
Measured Outcome: Learner Knowledge, Learner/Team Competence
Provider Ship: Jointly Provided
Registration: Open to all

Assessing Patient Safety and Mortality Risk Associated with Atypical Antipsychotic Use versus Pimavanserin in Management of Parkinson's disease Psychosis (PDP)

Contact us

Sign up for the expert list